Total Payments
$26,906
2024 Payments
$2,906
Companies
99
Transactions
1,156
Medicare Patients
6,458
Medicare Billing
$1.5M
Payment Breakdown by Category
Food & Beverage$20,282 (75.4%)
Consulting$4,483 (16.7%)
Education$1,348 (5.0%)
Travel$793.42 (2.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $20,282 | 1,120 | 75.4% |
| Consulting Fee | $4,483 | 2 | 16.7% |
| Education | $1,348 | 31 | 5.0% |
| Travel and Lodging | $793.42 | 3 | 2.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $4,540 | 35 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $2,522 | 50 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,593 | 94 | $0 (2024) |
| Genentech USA, Inc. | $1,506 | 61 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,466 | 85 | $0 (2024) |
| Amgen Inc. | $1,173 | 60 | $0 (2023) |
| Janssen Biotech, Inc. | $1,139 | 67 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,029 | 62 | $0 (2024) |
| PFIZER INC. | $969.73 | 72 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $660.54 | 30 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,906 | 151 | Merck Sharp & Dohme LLC ($231.77) |
| 2023 | $7,085 | 179 | Incyte Corporation ($3,799) |
| 2022 | $3,202 | 172 | Incyte Corporation ($220.14) |
| 2021 | $4,834 | 197 | AstraZeneca Pharmaceuticals LP ($1,884) |
| 2020 | $539.33 | 31 | Janssen Biotech, Inc. ($92.89) |
| 2019 | $3,930 | 177 | Genentech USA, Inc. ($545.26) |
| 2018 | $3,001 | 167 | Amgen Inc. ($440.53) |
| 2017 | $1,408 | 82 | E.R. Squibb & Sons, L.L.C. ($203.26) |
All Payment Transactions
1,156 individual payment records from CMS Open Payments — Page 1 of 47
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $22.44 | General |
| Category: Oncology | ||||||
| 12/30/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $13.65 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/19/2024 | Avyxa Pharma, LLC | Docivyx (Drug) | Food and Beverage | In-kind items and services | $33.59 | General |
| Category: Oncology | ||||||
| 12/18/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI | Food and Beverage | In-kind items and services | $8.42 | General |
| Category: ONCOLOGY | ||||||
| 12/17/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI | Food and Beverage | In-kind items and services | $3.39 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $18.77 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $15.14 | General |
| Category: Oncology | ||||||
| 12/11/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $17.30 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/11/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $15.52 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $22.83 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $18.76 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $17.78 | General |
| Category: Rare Disease | ||||||
| 12/03/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $26.23 | General |
| Category: Oncology | ||||||
| 11/27/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $16.56 | General |
| Category: Immunology | ||||||
| 11/26/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $18.86 | General |
| Category: Oncology | ||||||
| 11/25/2024 | Merck Sharp & Dohme LLC | WELIREG (Drug) | Education | In-kind items and services | $18.09 | General |
| Category: ONCOLOGY | ||||||
| 11/24/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Education | In-kind items and services | $18.09 | General |
| Category: ONCOLOGY | ||||||
| 11/22/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $29.76 | General |
| 11/22/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $18.41 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/21/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $26.99 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $20.14 | General |
| Category: Hematology/Oncology | ||||||
| 11/15/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $16.77 | General |
| Category: CELLT | ||||||
| 11/13/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $15.85 | General |
| Category: Oncology | ||||||
| 11/07/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $14.92 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $28.84 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 43 | 2,196 | 32,101 | $2.0M | $860,531 |
| 2022 | 43 | 2,002 | 52,618 | $842,880 | $336,282 |
| 2021 | 44 | 1,996 | 35,535 | $873,746 | $316,454 |
| 2020 | 10 | 264 | 1,364 | $153,280 | $33,667 |
Total Patients
6,458
Total Services
121,618
Medicare Billing
$1.5M
Procedure Codes
140
All Medicare Procedures & Services
140 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 12 | 9,400 | $864,800 | $405,004 | 46.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 19 | 7,860 | $306,360 | $145,225 | 47.4% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 45 | 5,300 | $192,200 | $87,935 | 45.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 257 | 809 | $135,103 | $75,823 | 56.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 52 | 277 | $93,072 | $27,057 | 29.1% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 17 | 61 | $52,033 | $20,996 | 40.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 56 | 99 | $24,057 | $13,271 | 55.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 502 | 1,379 | $34,475 | $10,369 | 30.1% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 15 | 1,730 | $25,950 | $8,837 | 34.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 71 | 71 | $19,241 | $8,459 | 44.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 43 | 43 | $14,835 | $7,257 | 48.9% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 26 | 98 | $18,130 | $4,763 | 26.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 59 | 74 | $8,510 | $4,582 | 53.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 71 | 94 | $17,296 | $4,401 | 25.4% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 11 | 75 | $8,550 | $4,063 | 47.5% |
| 82024 | Adrenocorticotropic hormone (acth) level | Office | 2023 | 34 | 106 | $9,646 | $4,012 | 41.6% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 38 | 162 | $13,932 | $3,542 | 25.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 94 | 331 | $12,578 | $3,303 | 26.3% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 147 | 218 | $7,194 | $2,884 | 40.1% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 56 | 148 | $5,920 | $2,436 | 41.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 27 | 172 | $10,148 | $2,019 | 19.9% |
| 99195 | Drawing of blood for a medical problem | Office | 2023 | 15 | 28 | $4,060 | $1,945 | 47.9% |
| 82533 | Cortisol (hormone) measurement, total | Office | 2023 | 35 | 108 | $4,212 | $1,725 | 40.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 11 | 11 | $3,465 | $1,484 | 42.8% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 32 | 58 | $7,076 | $1,361 | 19.2% |
About Dr. Colin Curran, MD
Dr. Colin Curran, MD is a Hematology & Oncology healthcare provider based in Hickory, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/02/2005. The National Provider Identifier (NPI) number assigned to this provider is 1003810383.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Colin Curran, MD has received a total of $26,906 in payments from pharmaceutical and medical device companies, with $2,906 received in 2024. These payments were reported across 1,156 transactions from 99 companies. The most common payment nature is "Food and Beverage" ($20,282).
As a Medicare-enrolled provider, Curran has provided services to 6,458 Medicare beneficiaries, totaling 121,618 services with total Medicare billing of $1.5M. Data is available for 4 years (2020–2023), covering 140 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Hickory, NC
- Active Since 06/02/2005
- Last Updated 01/28/2026
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1003810383
Products in Payments
- CALQUENCE (Drug) $1,881
- OPDIVO (Biological) $781.10
- KEYTRUDA (Biological) $761.74
- Lenvima (Drug) $548.39
- TECENTRIQ (Biological) $449.15
- INJECTAFER (Drug) $396.85
- KISQALI (Drug) $331.04
- Prolia (Biological) $310.90
- XTANDI (Drug) $307.79
- JAKAFI (Drug) $300.55
- JEVTANA (Drug) $292.91
- IMBRUVICA (Drug) $278.65
- EMPLICITI (Biological) $271.51
- ELIQUIS (Drug) $267.70
- OCREVUS (Biological) $258.43
- IBRANCE (Drug) $213.13
- VENCLEXTA (Drug) $209.01
- CABOMETYX (Drug) $207.30
- LIBTAYO (Biological) $204.07
- ICLUSIG (Drug) $201.16
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.